lung-tab

DUPIXENT showed improvement in LUNG FUNCTION

Lung function improvement was seen as early as Week 2 and sustained through
Week 52

Post-bronchodilator FEV₁

Change in post‑bronchodilator FEV₁ from baseline at Week 12 and Week 52 (ITT population; secondary endpoint)¹

Placebo + triple therapy (n=471) DUPIXENT + triple therapy (n=468)

LSM change from baseline (mL)

158 mL

84 mL

138 mL

58 mL

Week 2

Weeks

Pre-bronchodilator FEV₁

Significant improvements of similar magnitude were observed in change from baseline in pre-bronchodilator FEV₁ at Weeks 12 and 52 in subjects treated with DUPIXENT compared to placebo across the BOREAS and NOTUS trials.¹

Patients administered DUPIXENT + triple therapy saw numerical improvement in post‑bronchodilator FEV₁ of 134 mL at Week 12 (n=470) and 127 mL at Week 52 (n=362), compared with 67 mL at Week 12 (n=465) and 59 mL at Week 52 (n=359) in patients receiving placebo + triple therapy (LSM change from baseline, ITT population).¹

Post-bronchodilator lung function results are descriptive. Definitive conclusions cannot be made.

Triple therapy consisted of LAMA+LABA+ICS.¹

BL, baseline; COPD, chronic obstructive pulmonary disease; FEV₁, forced expiratory volume in 1 second; ICS, inhaled corticosteroid; ITT, intention-to-treat; LABA, long-acting beta agonist; LAMA, long-acting muscarinic antagonist; LSM, least squares mean.